Aripiprazole as a safer alternative for reproductive-age females with schizophrenia spectrum disorder: a case series
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242622Keywords:
Case series, Schizophrenia, Serum prolactin, Galactorrhea, Antipsychotics, Reproductive age, Females, Side effectAbstract
This case series investigates the use of aripiprazole as a safer alternative for reproductive-age females with schizophrenia experiencing galactorrhea due to antipsychotic treatment, primarily risperidone. Galactorrhea, the spontaneous discharge of breast milk, is a distressing side effect associated with elevated serum prolactin levels induced by certain antipsychotics. In three cases, females aged 30 to 40 diagnosed with schizophrenia and well-maintained on risperidone developed galactorrhea. Seeking to address both schizophrenia symptoms and galactorrhea, a gynecologist initiated cabergoline treatment to regulate prolactin levels. Simultaneously, the patients underwent a gradual transition from risperidone to aripiprazole. Over the course of the study, aripiprazole effectively mitigated galactorrhea, normalized serum prolactin levels, and maintained the stability of schizophrenia treatment. This case series suggests that aripiprazole may serve as a beneficial alternative for reproductive-age females, offering a balance between managing psychiatric symptoms and minimizing distressing side effects. Further research is warranted to validate these findings and explore the broader implications of aripiprazole in similar clinical contexts.
References
Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Curr Neuropharmacol. 2018;16(8):1210-23.
Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008;22(2):12-9.
Kaiser UB. Hyperprolactinemia and infertility: new insights. J Clin Investig. 2012;122(10):3467-8.
Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physio pathology, clinical features and guidance. Encephale. 2014;40(1):86-94.
Inder WJ, Castle D. Antipsychotic-Induced Hyperprolactinaemia. Austr N Zeal J Psychiatry. 2011;45(10):830-7.
Tuplin EW, Holahan MR. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Curr Neuropharmacol. 2017;15(8):1192-207.
Keck PE Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003;12(4):655-62.
Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, et al. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol. 2006;535(1-3):135-44.
Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70(10):1348-57.
Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One. 2013;8:e70.
Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518-22.
